Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma

Cancer Cell International

Guojun Zhang²  Guoqiang Zhao³  Wenqiao Zang³  Yuanyuan Wang³  Yuwen Du³  Xiaonan Chen³  Shaozhi Dun²  Yong Bai²  Shanshan Chen²  Rui Yang²  Wei Zhao¹  Ping Li²  Juan Li² 

[1] Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China

关键词: DLX6;    Microarray assay;    LAC;    lncRNA DLX6-AS1;   

Others  :  1217734
DOI  :  10.1186/s12935-015-0201-5

 received in 2014-12-15, accepted in 2015-04-22,  发布年份 2015

【 摘 要 】

Background

Lung adenocarcinoma (LAC), the primary histological type of non-small cell lung cancer (NSCLC), has displayed an increasing incidence and mortality worldwide. However, therapeutic approaches were limited. Dysregulation of some lncRNAs has been shown in various types of cancers including LAC. The aim of the present study was to vertify lncRNA DLX6-AS1 expression in LAC.

Methods

Microarray assay revealed expression profile of lncRNAs in LAC. qRT-PCR ( quantitative reverse transcription PCR) was performed to identify lncRNA DLX6-AS1 expression level in 72 paired LAC and adjacent normal lung tissues. qRT-PCR and Western blotting were used to verify that down-regulation lncRNA DLX6-AS1 decreased DLX6 (distal-less homeobox 6) mRNA and protein expression.

Results

Microarray analysis identified up-regulation of 272 lncRNAs and down-regulation of 635 lncRNAs in LAC tissues. The expression level of lncRNA DLX6-AS1 in LAC tissues was significantly higher compared to paired adjacent normal lung tissues (P< 0.05). In addition, its expression level was closed correlated with both histological differentiation (P = 0.004) and TNM stage (P = 0.033). qRT-PCR and Western blotting analysis showed that DLX6 mRNA and protein levels were lower in si-LncRNA group than in the NC (negative control) and Blank groups.

Conclusions

Microarray analysis identified that lncRNA DLX6-AS1 was up-regulated in LAC tissues. High DLX6-AS1 expression levels were significantly associated with both histological differentiation and TNM stage. Down-regulation of lncRNA DLX6-AS1 expression decreased the DLX6 mRNA and protein levels.

【 授权许可】

   
2015 Li et al.

【 图 表 】

Figure 1.

Figure 1.

Fig. 1.

【 参考文献 】

• [1]Chen WQ, Zheng RS, Zhang SW, Zou XN, Zhao P, He J. Lung cancer incidence and mortality in China. Thorac Cancer. 2013; 4:102-8.
• [2]Jemal A, Siegel R, Xu J, Ward E. Cancer statistic. CA Cancer J Clin. 2010; 60:277-300.
• [3]Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014; 64:9-29.
• [4]DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL et al.. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014; 64(4):252-71.
• [5]Pastorino U. Lung cancer screening. Br J Cancer. 2010; 102:1681-6.
• [6]Travis WD. Pathology of lung cancer. Clin Chest Med. 2011; 32:669-92.
• [7]Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, Yang JS et al.. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer. 2012; 12:348. BioMed Central Full Text
• [8]Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G et al.. The non-coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013; 73(3):1180-9.
• [9]Van Roosbroeck K, Pollet J, Calin GA. MiRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013; 13:183-204.
• [10]Finishing the euchromatic sequence of the human genome. Nature. 2004; 431:931-45.
• [11]Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006; 15(Spec No 1):R17-29.
• [12]Eddy SR. Non-coding RNA genes and the modern RNA world. Nat Rev Genet. 2001; 2:919-29.
• [13]Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ et al.. Long non-coding RNA HOTAIR reprogramschromatin state to promote cancer metastasis. Nature. 2010; 464(7291):1071-6.
• [14]Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH et al.. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010; 42(12):1113-7.
• [15]Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y et al.. CREB upregulates long non-coding RNA, HULC expression through interaction withmicroRNA-372 in liver cancer. Nucleic Acids Res. 2010; 38(16):5366-83.
• [16]Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS et al.. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011; 71(11):3852-62.
• [17]Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX et al.. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011; 54(5):1679-89.
• [18]Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y et al.. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol. 2013; 31(7):1117-23.
• [19]Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X et al.. Long non-coding RNA UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012; 41(1):276-84.
• [20]Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW et al.. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis. 2011; 32(11):1655-9.
• [21]Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J IntMed Res. 2011; 39(6):2119-28.
• [22]Li X, Jiang XY, Ge J, Wang J, Chen GJ, Xu L et al.. Aberrantly expressed lncRNAs in primary varicose great saphenous veins. PLOS ONE. 2014; 9:e86156.
• [23]Dong R, Jia D, Xue P, Cui X, Li K, Zheng S et al.. Genome-wide analysis of long noncoding RNA (lncRNA) expression in hepatoblastoma tissues. PLOS ONE. 2014; 9:e85599.
• [24]Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A et al.. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 2014; 5:764-74.
• [25]Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J et al.. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013; 49:2949-59.
• [26]Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY. Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol. 2013; 19:3658-64.
• [27]Jiang YJ, Bikle DD. LncRNA: a new player in 1α, 25 (OH) 2 vitamin D3/VDR protection against skin cancer formation. Exp Dermatol. 2014; 23:147-50.
• [28]Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R et al.. HOTAIR is a negative prognostic factor and exhibits prooncogenic activity in pancreatic cancer. Oncogene. 2013; 32(13):1616-25.
• [29]Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM et al.. MALAT-1, a novel noncoding RNA, and thymosin beta 4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22(39):8031-41.
• [30]Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H et al.. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014; 110:164-71.
• [31]Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007; 26(6):851-8.
• [32]Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41.
• [33]Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al.. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009; 106(28):11667-72.
• [34]Perez DS, Hoage TR, Pritchett JR, Ducharme SAL, Halling ML, Ganapathiraju SC et al.. Abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2008; 17:642-55.
• [35]Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G et al.. lncRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011; 477:295-300.
• [36]Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G et al.. Long non-coding RNA-MVIH promotes angiogenesis and serves as a predictor for HCC patients’ poor recurrence-free survival after hepatectomy. Hepatology. 2012; 56(6):2231-41.
• [37]Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012; 31:4577-87.
• [38]Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol. 2007; 170:1594-606.
• [39]Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat. 2005; 90:241-7.
• [40]Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z et al.. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res. 2008; 68:1296-302.
• [41]Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR. Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res. 2010; 70:9197-206.
• [42]Kato T, Sato N, Takano A, Miyamoto M, Nishimura H, Tsuchiya E et al.. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res. 2008; 14:2363-70.
• [43]Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G et al.. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer. 2010; 10:649. BioMed Central Full Text
• [44]Xu J, Testa JR. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC. J Biol Chem. 2009; 284:20593-601.
• [45]Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 2008; 3:1101-8.